Targeting the vasculature of solid tumors

F. J. Burrows, P. E. Thorpe

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Immunotoxins and other antibody-based therapeutic reagents have proved effective against lymphomas and leukemias but results with carcinomas and other solid tumors have thus far proved disappointing. A major reason for this difference is that solid tumors are relatively impermeable to macromolecules. A solution to this problem would be to attack the endothelial cells of the tumor vascular bed rather than the tumor cells themselves. We have developed a mouse model of this 'vascular targeting' approach where genetic modification of the tumor cells causes them to induce the expression of an experimental marker (MHC Class II) on tumor endothelium. In this report we show that an anti-Class II-deglycosylated Ricin A-chain immunotoxin kills activated endothelial cells in tissue culture and, when injected into appropriate tumor-bearing mice, causes complete thrombosis of the tumor vasculature and dramatic regressions of large solid tumors. These findings suggest that therapeutic agents derived from recently-described antibodies against human tumor endothelium could provide a general treatment for disseminated solid cancers in man.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalJournal of Controlled Release
Volume28
Issue number1-3
DOIs
StatePublished - 1994

Fingerprint

Neoplasms
Immunotoxins
Endothelium
Endothelial Cells
Ricin
Antibodies
Blood Vessels
Lymphoma
Leukemia
Thrombosis
Therapeutics
Carcinoma

Keywords

  • Antibody
  • Endothelial cell
  • Immunotoxin
  • Solid tumor
  • Therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Targeting the vasculature of solid tumors. / Burrows, F. J.; Thorpe, P. E.

In: Journal of Controlled Release, Vol. 28, No. 1-3, 1994, p. 195-202.

Research output: Contribution to journalArticle

Burrows, F. J. ; Thorpe, P. E. / Targeting the vasculature of solid tumors. In: Journal of Controlled Release. 1994 ; Vol. 28, No. 1-3. pp. 195-202.
@article{66b0209246d1429c9d74a8359079c4c3,
title = "Targeting the vasculature of solid tumors",
abstract = "Immunotoxins and other antibody-based therapeutic reagents have proved effective against lymphomas and leukemias but results with carcinomas and other solid tumors have thus far proved disappointing. A major reason for this difference is that solid tumors are relatively impermeable to macromolecules. A solution to this problem would be to attack the endothelial cells of the tumor vascular bed rather than the tumor cells themselves. We have developed a mouse model of this 'vascular targeting' approach where genetic modification of the tumor cells causes them to induce the expression of an experimental marker (MHC Class II) on tumor endothelium. In this report we show that an anti-Class II-deglycosylated Ricin A-chain immunotoxin kills activated endothelial cells in tissue culture and, when injected into appropriate tumor-bearing mice, causes complete thrombosis of the tumor vasculature and dramatic regressions of large solid tumors. These findings suggest that therapeutic agents derived from recently-described antibodies against human tumor endothelium could provide a general treatment for disseminated solid cancers in man.",
keywords = "Antibody, Endothelial cell, Immunotoxin, Solid tumor, Therapy",
author = "Burrows, {F. J.} and Thorpe, {P. E.}",
year = "1994",
doi = "10.1016/0168-3659(94)90166-X",
language = "English (US)",
volume = "28",
pages = "195--202",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Targeting the vasculature of solid tumors

AU - Burrows, F. J.

AU - Thorpe, P. E.

PY - 1994

Y1 - 1994

N2 - Immunotoxins and other antibody-based therapeutic reagents have proved effective against lymphomas and leukemias but results with carcinomas and other solid tumors have thus far proved disappointing. A major reason for this difference is that solid tumors are relatively impermeable to macromolecules. A solution to this problem would be to attack the endothelial cells of the tumor vascular bed rather than the tumor cells themselves. We have developed a mouse model of this 'vascular targeting' approach where genetic modification of the tumor cells causes them to induce the expression of an experimental marker (MHC Class II) on tumor endothelium. In this report we show that an anti-Class II-deglycosylated Ricin A-chain immunotoxin kills activated endothelial cells in tissue culture and, when injected into appropriate tumor-bearing mice, causes complete thrombosis of the tumor vasculature and dramatic regressions of large solid tumors. These findings suggest that therapeutic agents derived from recently-described antibodies against human tumor endothelium could provide a general treatment for disseminated solid cancers in man.

AB - Immunotoxins and other antibody-based therapeutic reagents have proved effective against lymphomas and leukemias but results with carcinomas and other solid tumors have thus far proved disappointing. A major reason for this difference is that solid tumors are relatively impermeable to macromolecules. A solution to this problem would be to attack the endothelial cells of the tumor vascular bed rather than the tumor cells themselves. We have developed a mouse model of this 'vascular targeting' approach where genetic modification of the tumor cells causes them to induce the expression of an experimental marker (MHC Class II) on tumor endothelium. In this report we show that an anti-Class II-deglycosylated Ricin A-chain immunotoxin kills activated endothelial cells in tissue culture and, when injected into appropriate tumor-bearing mice, causes complete thrombosis of the tumor vasculature and dramatic regressions of large solid tumors. These findings suggest that therapeutic agents derived from recently-described antibodies against human tumor endothelium could provide a general treatment for disseminated solid cancers in man.

KW - Antibody

KW - Endothelial cell

KW - Immunotoxin

KW - Solid tumor

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0028207108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028207108&partnerID=8YFLogxK

U2 - 10.1016/0168-3659(94)90166-X

DO - 10.1016/0168-3659(94)90166-X

M3 - Article

AN - SCOPUS:0028207108

VL - 28

SP - 195

EP - 202

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1-3

ER -